Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leena Vehmanen

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|May 19, 2016
[Male breast cancer]Johanna Mattson, Leena Vehmanen
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Bisphosphonates and breast cancer]Leena Vehmanen, Tiina Saarto
Acta Oncologica (Stockholm, Sweden)|November 17, 2004
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patientsTiina Saarto, Leena Vehmanen, Pekka Virkkunen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual statusLeena Vehmanen, Inkeri Elomaa, Carl Blomqvist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancerTiina Saarto, Leena Vehmanen, Carl Blomqvist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinomaSirpa Leppä, Tiina Saarto, Leena Vehmanen, et al.
Breast Cancer Research and Treatment|September 21, 2004
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failureLeena Vehmanen, Tiina Saarto, Juha Risteli, et al.
Breast Cancer Research and Treatment|March 12, 2021
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trialMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Breast Cancer Research and Treatment|July 26, 2023
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurementMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Breast Cancer Research and Treatment|December 27, 2024
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trialMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Duodecim; Laaketieteellinen Aikakauskirja|May 19, 2016
[Male breast cancer]Johanna Mattson, Leena Vehmanen
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Bisphosphonates and breast cancer]Leena Vehmanen, Tiina Saarto
Acta Oncologica (Stockholm, Sweden)|November 17, 2004
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patientsTiina Saarto, Leena Vehmanen, Pekka Virkkunen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual statusLeena Vehmanen, Inkeri Elomaa, Carl Blomqvist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancerTiina Saarto, Leena Vehmanen, Carl Blomqvist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinomaSirpa Leppä, Tiina Saarto, Leena Vehmanen, et al.
Breast Cancer Research and Treatment|September 21, 2004
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failureLeena Vehmanen, Tiina Saarto, Juha Risteli, et al.
Breast Cancer Research and Treatment|March 12, 2021
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trialMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Breast Cancer Research and Treatment|July 26, 2023
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurementMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Breast Cancer Research and Treatment|December 27, 2024
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trialMária Faltinová, Leena Vehmanen, Heli Lyytinen, et al.
Pageof 3